

1/8




FIG. 1A




FIG. 1B




FIG. 1C



FIG. 2A





FIG. 2B



FIG. 2C



SEP 2 0 2004 B
MADEMARK

TSU-Pr (human prostate) tumor	#1	#5	#3	#4	42	9#
Initial tumor implant weight (mg)	53.00	52.00	53.00	54.00	54.00	53.00
After 7 days, control tumor weight (mg)	69.90	66.10	62.50	75.00	92.70	72.90
After 7 days: Initial wt = Total Increase in Control	16.70	12.90	9.30	21.80	39.50	19.70
Tumors with acetyl- SNS-carboxamide						
45 μg acetyl-acetyl- SNS-carboxamide	48.00	44.70	53.50	56.80	49.70	58.20
After 7 days: Inhibitor weight – Initial Implant weight	-5.20	-8.50	0.30	3.60	-3.50	5.00
% of Total weight	-28.06	-45.87	1.62	19.43	-18.89	26.98
% Inhibition of tumor wt by acetyl-SNS- carboxamide	128.06	145.87	98.38	80.57	118.89	73.02

FIG. 3A

OTO E TOTO
SEP 2 0 SOUN SHE
THE DESIGNATION OF THE PERSON

TSU-Pr (human prostate) tumor	L#	8#	6#	#10	MEAN	STD	SEM	
Initial tumor implant weight (mg)	54.00	54.00	52.00	53.00	53.20	0.79	0.35	
After 7 days, control tumor weight (mg)	72.50	67.40	78.00	67.40	72.44	8.46	2.99	
After 7 days: Initial wt = Total Increase in Control	15.90	15.90	16.70	16.90	18.53	8.11	2.56	
Tumors with acetyl- SNS-carboxamide			*				# 1 To 1 T	· · · :
45 µg acetyl-acetyl- SNS-carboxamide	48.60	47.40	46.80	58.40			An Theorem	
After 7 days: Inhibitor weight – Initial Implant weight	-4.60	-5.80	-6.40	5.20	51.21	5.09	1,61	
% of Total weight	-24.82	-31.30	-34.54	28.06				
% Inhibition of tumor wt by acetyl-SNS- carboxamide	124.82	131.30	134.54	71.94	110.74	27.45	89.8	

F 16, 38

611	E SCIQ
SEP	2 0 2004 2
BREI	RADEMARKS

SNS Tag ID	Tube Length (mm) 5 μ g/mL/well	" Inhibition	SEM	Angiogenesis Index 15 µg/CAM	% Inhibition
EBM Control	0.7206 +/- 0.03			51 +/- 9.7	
Growth Factor Control	1.7886 +/- 0.09			162.22 +/- 15.3	
S_A_S	1.4564 +/- 0.14	31.103	15.053		
S_0_S	1.0423 +/- 0.12	63.879	18.343	70.66 +/- 7.4	82.31 +/- 6.6
S_N_S	1.5152 +/- 0.06	25.597	8.8465		
s_n_s	1.8351 +/- 0.07	-4.3596	6.688		
S_0_S	1.3653 +/- 0.08	39.632	11.725		
S_E_S	1.9891 +/- 0.08	-18.776	11.056		
S_N_S	1.3186 +/- 0.09	44.008	9.718		
S_n_S	1.9624 +/- 0.15	-16.273	23.402		
S_0_S	1.9624 +/- 0.15	32.935	14.458		

Continued on Fig. 4B FIG. 4A



Continued from Fig. 4A

SNS Tag ID	Tube Length (mm) 5 µg/mL/well	, Inhibition	SEM	Angiogenesis Index 15 µg/CAM	% Inhibition
S_n_S	1.6803 +/- 0.06	10.141	6.3189		
S_N_S	1.2702 +/- 0.22	48.54	34.054	85.55 +/- 9.1	68.93 +/- 8.19
S_n_s	1.3933 +/- 0.06	37.014	9.3608		
t4Hyp_N_S	1.3244 +/- 0.08	43.462	9.173		
t4Hyp_N_t4Hyp	1.9347 +/- 0.18	-13.679	28.834		
S_N_t4Hyp	0.6404 +/- 0.07	107.51	11.263	82.89 +/- 9.6	71.33 +/- 8.27
S_N_S	60.0 -/+ 6668.0	83.213	10.167	77.11 +/- 11.1	76.52 +/- 9.4
Control 8A029	0.9606 +/- 0.16	77.523	25.513		·

This data represents triplicate wells/peptide. 9 images/well 35.000 human endothelial cells/well

This data represents N = 6 to 9 in FGF2-stimulated CAM model

FIG. 4B






FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 5F




FIG. 56

